Nucleix Stock

Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests.

Sign up today and learn more about Nucleix Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Nucleix Stock

Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Its sensitive and specific tests are based on identification of subtle changes in methylation patterns. Nucleix offers a urine test for monitoring of bladder cancer called Bladder EpiCheck and a blood test for early detection of lung cancer called Lung EpiCheck. Adam Wasserstrom, Danny Frumkin, and Elon Ganor founded it in 2008, with its headquarters in Rehovot in Israel.

Funding History

January 2015$50K
May 2016$3.0M
July 2018$2.5M
April 2021$55.0M
January 2022$22.0M

Management

Co-founder, VP Software & Analytics

Adam Wasserstrom

VP Research & Co-founder

Danny Frumkin

Chief Executive Officer

Chris Hibberd

Member of Board of Directors

Dan J. Gelvan

Chief Financial Officer

W. Todd Myers

Executive Chairman

Chris Hibberd

Press

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo